Atrial Fibrillation & Anticoagulants Margaret Jin, BScPhm, PharmD, MSc, CDE Hamilton Family Health Team May 27, 2014 Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline Case Presentation Canadian Cardiovascular Society 2012 Recommendations Dabigatran (Pradaxa®) Rivaroxaban (Xarelto®) Apixaban (Eliquis®) Summary Questions Case Mr. AF, a 70 y male with Hypertension (BP=135/85) and history of GERD. He was just diagnosed with non-valvular permanent atrial fibrillation Normal renal and liver function Current meds: ◦ ◦ ◦ ◦ ◦ Ramipril 10mg once daily Bisoprolol 5mg once daily Amlodipine 5mg once daily Rabeprazole 20mg once daily No OTCs Smokes 25 cigs/d x 55 years, drinks no alcohol ODB drug plan BP=Blood Pressure, GERD=GastroEsophageal Reflux Disease, ODB=Ontario Drug Benefit, OTCs=Over-the-counters Anticoagulation options What anticoagulant (if any), would you give? ◦ ◦ ◦ ◦ ◦ ◦ None? Aspirin? Warfarin? Dabigatran? Rivaroxaban? Apixaban? Assess Thromboembolic Therapy Three Steps 1. Assess Thromboembolic Risk a. CHADS2 Risk Criteria 2. Assess Bleeding Risk a. HAS-BLED Risk Criteria 3. Assess Benefit vs. Risk 1. Assessing Thromboembolic Risk CHADS2 Risk Criteria Points Congestive Heart Failure 1 (symptoms in the last 3 months) Hypertension (diagnosis) 1 Age ≥ 75 years 1 Diabetes mellitus 1 Stroke/Transient Ischemic Attack (prior) 2 What is Mr. AF’s CHADS2 score? Recommended Therapy CHADS2 Stroke Rate %/yr Canadian Cardiology Society (CCS) 2012 Recommendations 0 1.9 No additional risk factors: No antithrombotic Female or vascular disease: ASA 75-325mg daily Age ≥ 65 yrs or female & vascular disease: OAC 1 2.8 OAC preferred Alternatives: ASA 75-325mg daily 2 4 3 5.9 4 8.5 5 12.5 6 18.2 Oral anticoagulant (OAC) When OAC is indicated, most patients should receive dabigatran, rivaroxaban, or apixaban in preference to warfarinCCS 2012 ASA=Acetylsalicylic Acid, OAC=oral anticoagulant 2. Assessing Bleeding Risk HAS-BLED Risk Criteria Hypertension (SBP > 160 mmHg) Abnormal renal (transplantation, dialysis, SCr > 200umol/L) or liver function (AST/ALT>3xULN, bilirubin>2xULN) (1 point each) Points 1 1 to 2 Stroke (caused by a bleed) 1 Bleeding (hospitalization, decrease Hgb > 20g/L, transfusion) 1 Labile INRs (therapeutic range < 60%) 1 Elderly (age > 65 years) 1 Drugs (ASA/NSAID) or alcohol (≥8 drinks/week) (1 point each) 1 to 2 What is Mr. AF’s HAS-BLED score? ASA=acetylsalicylic acid, AST=aspartate aminotransferase, ALT=alanine aminotransferase, Hgb=hemoglobin, INRs=international normalized ratios, NSAIDS=non-steroidal anti-inflammatory drugs, SCr=serum creatinine, ULN=upper limit of normal HAS-BLED Score & Major Bleeds HAS-BLED Score Major Bleeds (%/yr) 0 1 2 1.13 1.02 1.88 3 4 5 3.74 8.70 12.50 Major bleed Intracranial, hospitalization, decrease Hgb > 20g/L, +/transfusion NOTE: HAS-BLED Score & Major Bleed risk is only validated with warfarin 3. Assess Risk vs. Benefit – Mr. AF CHADS2 = 1 = 2.8%/yr Stroke rate HAS-BLED = 1 = 1.02%/yr Major bleed Risk of stroke > Major Bleed Risk Recommendation: Oral anticoagulants ◦ ◦ ◦ ◦ Warfarin Dabigatran Apixaban Rivaroxaban Preferred by Canadian Cardiology Society 2012 guidelines ODB – Limited Use for newer agents ODB=Ontario Drug Benefit Ontario Drug Benefit – Limited Use For the prevention of stroke and systemic embolism in at risk patients with non-valvular atrial fibrillation AND in whom: 1. Anticoagulation is inadequate {at least 35% of the tests are outside of range} following a reasonable trial {at least 3 months} of warfarin; OR 2. Anticoagulation with warfarin is contraindicated or not possible due to inability to regularly monitor via INR testing (i.e., No access to INR testing services at a lab, clinic, pharmacy & home) Mr. AF Mr. AF is prescribed warfarin 2 years later, Mr. AF’s wife died and Mr. AF is unable to cope – started drinking INR levels fluctuating over 3 months Time for a new oral anticoagulant ◦ Dabigatran? (Oct 2010, LU April 2012) ◦ Rivaroxaban? (Dec 2012, LU Aug 2013 ◦ Apixaban? (Jan 2012, LU July 2012) LU=Limited Use Oral anticoagulants Direct thrombin inhibitor Dabigatran Direct thrombin inhibitor Half-life: 12-17 hours Dose: 150mg bid ◦ 110mg bid if ≥ 80y or 75-79y with ≥ 1 bleeding risk factor* Renal function ◦ CrCl<30mL/min contraindicated No antidote No dosette/blisterpack or open capsule *Bleeding RF = moderate renal impairment (30-50mL/min), P-gp inhibitor, NSAID, anti-platelets, congenital/aquired coagulation disorders, thrombocytopenia or functional platelet defects, active/recent ulcerative GI bleeding, recent biopsy or major trauma, recent intracranial hemorrhage, surgery (brain, spinal or opthalmic), bacterial endocarditis Dabigatran – Drug Interactions Contraindicated ◦ Dronedarone, ketoconazole Avoid: rifampicin ◦ Increase dabigatran concentration: P-gp inhibitors (i.e., amiodarone, clarithromycin, cyclosporine, itra-, posa-conazole, quinidine, tacagrelor, tacrolimus, verapamil, etc) ◦ Decrease dabigatran concentration P-gp inducers (i.e., carbamazepine, St. John’s Wort, tenofovir) Antacids (H2RA, PPI, Al-Mg Hydroxide) H2RA=Histamine2 Receptor Antagonist, P-gp=P-glycoprotein, PPI=proton pump inhibitor, Al-Mg=aluminum-magnesium Dabigatran vs. Warfarin – RE-LY NEJM 2009;361:1139-51 RCT, dabigatranblinded, warfarinopen-label Intervention: ◦ Dabigatran 150mg bid vs. dabigatran 110mg bid vs. warfarinINR 2-3 Inclusion: AF & ≥ 1 of the following: ◦ Previous stroke/TIA, LVEF<40, NYHA class II-IV HF within 6 months, ≥ 75y or 65-74y + DM, HTN or CAD Exclusion: ◦ Severe heart-valve disorder, stroke within 14 days prior or severe stroke within 6 months prior, CrCl<30mL/min, active liver disease, conditions that increase risk of bleed AF=atrial fibrillation, CAD=coronary artery disease, CrCl=creatinine clearance, DM=diabetes mellitus, HF=heart failure, HTN=hypertension, LVEF=left ventricular ejection fraction, NYHA=New York Heart Association, RCT=randomized control trial, TIA=transient ischemic attack, y=year RE-LY results NEJM 2009;361:1139-51 N=18,113 non-valvular AF pts at risk of stroke CHADS2 mean = 2.1 Mean time in therapeutic range with warfarin was 64% Median follow up = 2 years RE-LY results Dabigatran (both doses) vs. warfarin ◦ ◦ ◦ ◦ NEJM 2009;361:1139-51 Less hemorrhagic stroke & intracranial bleeds More dyspepsia Trend for higher MI? Higher discontinuation rate with dabigatran Dabigatran 150mg bid vs. warfarin ◦ Superior to warfarin for stroke/SE (NNT=88) ◦ Superior for ischemic/hemorrhagic stroke ◦ Increase GI bleeds (NNH=100) Dabigatran 110mg bid vs. warfarin ◦ Non-inferior to warfarin for stroke/SE ◦ Less major bleeds (NNT=77) Would you give Mr. AF dabigatran? Yes, maybe? No, maybe not? Dabigatran 150mg bid He is on a PPI – potential superior to warfarin in drug interaction – unclear stroke or systemic about clinical significance embolism (~14% of RE-LY study patients were on PPI) To enhance the absorption of dabigatran, a low pH is required – dabigatran capsules contain dabigatrancoated pellets with a tartaric acid core More GI bleed No antidote The Hamilton Spectator February 15, 2014 Trials and errors? Mac, HHS sued over drug safety In an unprecedented case, McMaster University and Hamilton Health Sciences are facing lawsuits in the United States over the safety of the drug Pradaxa. As The Spectator's Steve Buist reports, the lawsuits allege that regulatory approval for the popular anticoagulant was partly based on tainted data from clinical trials led by Hamilton researchers. http://www.thespec.com/news-story/4369907-trial-and-errors-mac-hhs-suedover-drug-safety/ Oral anticoagulants Direct thrombin inhibitor Rivaroxaban Direct Factor Xa Inhibitor Half-life: 5-9h (young) or 11-13h (elderly) Dose: 20mg once daily ◦ CrCl 30-49mL/min: 15mg once daily Renal function ◦ CrCl < 30mL/min not recommended No antidote Rivaroxaban – Drug Interactions Contraindicated: Itra- keto- posacon-azoles, ritonavir CYP 3A4 and P-gp inducers (decrease rivaroxaban concentration) ◦ Carbamazepine, clarithromycin, phenytoin, rifampin, St. John’s Wort Rivaroxaban vs. Warfarin ROCKET-AF NEJM 2011;365:883-91 RCT, double-blinded Intervention: ◦ Rivaroxaban 20mg od vs. warfarinINR 2-3 ◦ Rivaroxaban 15mg od if CrCl 30-49mL/min Inclusion: ◦ Persistent/paroxysmal AF on ≥ 2 episodes, risk of future stroke/TIA or systemic embolism OR CHADS2 score ≥ 2 Exclusion: ◦ Stroke within 14 days or TIA within 3 days, anemia Hgb<100g/L, prosthetic heart valve, CrCl<30mL/min, active liver disease, conditions that increase risk of bleed AF=atrial fibrillation, CHADS2=Congestive heart failure, Hypertension, Age≥75, Diabetes, Stroke/Transient Ischemic Attack, CrCl=creatinine clearance, Hgb=Hemoglobin, RCT=randomized control trial, TIA=transient ischemic attack, y=year ROCKET-AF NEJM 2011;365:883-91 N=14,264 non-valvular AF pts at risk of stroke CHADS2 mean = 3.5 Mean time in therapeutic range with warfarin was 55% (North American sites: 64%) Median follow up per protocol = 590 days (1.6 years) Median follow up intention-to-treat = 707 days (1.9 years) ROCKET-AF NEJM 2011;365:883-91 Rivaroxaban vs. warfarin ◦ Rivaroxaban non-inferior to warfarin for stroke or systemic embolism ◦ Potential Benefits: Less hemorrhagic stroke (NNT=333) and systemic embolism (NNT=417) Less critical bleeding (NNT=167), less fatal bleeding (NNT=250), less intracranial bleeding (NNT=250) ◦ Potential Harms: More drop in Hgb ≥ 20g/L (NNH=143), more transfusions (NNH=200), more GI bleeds (NNH=100), more epistaxis (NNH=67), more hematuria (NNH=125) Would you give Mr. AF rivaroxaban? Yes, maybe? Rivaroxaban 20mg once daily noninferior to warfarin in stroke or systemic embolism Once daily dosing may be more attractive to Mr. AF No, maybe not? CHADS2 score = 1 More GI bleed No antidote Oral anticoagulants Direct thrombin inhibitor Apixaban Direct Factor Xa Inhibitor Half-life: 12 hours Dose: 5mg twice daily ◦ 2.5mg BID if pts with ≥ 2 of the following: Age ≥ 80, body weight ≤ 60kg, or Scr ≥ 133 umol/L Renal function ◦ Excluded patients with CrCl < 25mL/min ◦ CrCl < 15mL/min not recommended No antidote Apixaban – Drug Interactions Contraindications ◦ Itra- keto- posacon-azoles, ritonavir CYP 3A4 and P-gp inducers (decrease apixaban concentration) ◦ Carbamazepine, clarithromycin, phenytoin, rifampin, St. John’s Wort P-gp inhibitors (increase apixaban concentration) ◦ Amiodarone, dronedarone, quinidine, verapamil Apixaban vs. Warfarin ARISTOTLE NEJM 2011;365:981-92 RCT, double-blinded Intervention: ◦ Apixaban 5mg BID vs. warfarinINR 2-3 ◦ Apixaban 2.5mg BID in pts with ≥ 2 of the following: Age ≥ 80y, body weight ≤ 60kg, or SCr ≥ 133umol/Lmg od Inclusion: ◦ Permanent/persistent AF or flutter, ≥ 1 of the following stroke risk factors: age≥75y, prior stroke/TIA/systemic embolus, HF or LVEF≤40%, DM or HTN Exclusion: ◦ Stroke within 7 days, Hgb<90g/L, prosthetic heart valve, renal insufficiency (CrCl<25mL/min or SCr>221umol/L), active liver disease, conditions that increase risk of bleed, required ASA > 165mg/d, treatment with both ASA+thienopyridine ARISTOTLE Results NEJM 2011;365:981-92 N=18,201 non-valvular AF pts at risk of stroke CHADS2 mean = 2.1 Mean time in therapeutic range with warfarin was 62.2% Median follow-up = 1.8 years ARISTOTLE Results NEJM 2011;365:981-92 Apixaban vs. Warfarin ◦ Apixaban superior to warfarin for stroke and systemic embolism (NNT=167/1.8 years) ◦ Potential Benefits: Decrease stroke (NNT=175), decrease hemorrhagic stroke (NNT=238) and decrease mortality (NNT=132) Decrease major bleed (NNT=67) Intracranial bleed (NNT=128) Decreased d/c rates (NNT=45) Would you give Mr. AF apixaban? Yes, maybe? Apixaban 5mg twice daily superior to warfarin in stroke or systemic embolism Decrease all cause mortality No difference in GI bleeds compared to warfarin No, maybe not? Twice daily? No antidote Switching FROM Warfarin NOAC Check INR 2. Stop warfarin 3. Recheck INR in 2-4 days Start dabigatran when INR < 2.0CPS 1. ◦ Thrombosis Canada ≤ 2.0 Start rivaroxaban when INR ≤ 2.5CPS ◦ Thrombosis Canada ≤ 2.0 Start apixaban when INR < 2.0CPS ◦ Thrombosis Canada ≤ 2.0 What if? Mr. AF’s renal function declined: ◦ 72y male, SCr=130umol/L, Ht=65 inches, Wt=65kg, CrCl=39.5mL/min What would you give him if he could not take warfarin? ◦ Dabigatran 150mg or 110mg bid? ◦ Rivaroxaban 20mg or 15mg od? ◦ Apixaban 2.5mg or 5mg bid? Summary Warfarin advantages 60+ years experience Vitamin K antidote Valvular/non-valvular AF Allows for missed doses? No dosage requirements for renal dysfunction Monitoring – up to every 3 months Cost $40/month Warfarin disadvantages Many drug/food interactions Slow onset Physician/nurse/pharmaci st time? Seasonal changes in INR? Monitoring? Summary Novel oral anticoagulants Advantages Less Monitoring: ◦ SCr & CrCl at least annually Fast onset Disadvantages <2 years experience No antidote If miss dose, short half-life – quick “offset” Renal function dose adjustments Cost > $100/month Summary Warfarin is preferred in: ◦ ◦ ◦ ◦ ◦ Mechanical or valvular AF If INR is stable on warfarin CrCl < 30mL/min Liver dysfunction Poor compliance (or maybe no OAC is preferred) ◦ Morbidly Obese? Summary Dabigatran 150mg bid preferred if recent ischemic stroke on warfarin Rivaroxaban or apixaban is preferred: ◦ CrCl 30-50mL/min ◦ Dypepsia or upper GI bleed ◦ Recent acute coronary syndrome Apixaban preferred if recent GI bleed Rivaroxaban preferred if poor compliance with twice daily dosing or request for a once-daily regimen Questions?